Lamark Biotech

Executive Summary

Lamark Biotech is an Indian biotechnology firm pioneering thermostable biologics via its proprietary Proteostrong™ platform. By reformulating existing therapeutic proteins such as insulin, anti-VEGF agents for wet age-related macular degeneration (AMD), and lung-cancer antibodies, the company aims to eliminate cold-chain dependence, significantly lowering costs and improving access in emerging markets. Founded in 2018 and headquartered in Hyderabad, Lamark operates in the preclinical stage with a workforce of 50–200 employees, targeting high-demand therapeutic areas of diabetes, ophthalmology, and oncology. Its platform addresses a critical infrastructure gap in developing countries, where cold-chain logistics often hinder the distribution of biologics. If successful, Lamark's products could parallel the impact of established biosimilars but with added thermal stability, offering a competitive advantage in affordability and reach. The company's progress is closely watched given India's growing biotech ecosystem and the pressing need for accessible biologic therapies in low- and middle-income countries.

Upcoming Catalysts (preview)

• Q2 2027IND filing for lead thermostable insulin candidate50% success
• Q4 2026Series A funding round to advance pipeline60% success
• TBDStrategic partnership or licensing deal with a global pharma for anti-VEGF or insulin30% success